What's happening
This bill allows nurse practitioners to participate in collaborative drug therapy management with pharmacists and makes the program permanent.
Why it matters
Expands access to collaborative care. By including nurse practitioners (NPs) as eligible partners in collaborative drug therapy management with pharmacists, the bill increases the pool of healthcare providers who can participate, potentially improving patient access to team-based medication management, especially in underserved or rural areas where physicians may be in short supply.
Solidifies and broadens the program. Making the collaborative drug therapy management program permanent removes previous expiration dates, providing stability and predictability for healthcare institutions, pharmacists, and providers investing in these collaborative care models.
Allows new community practice sites. The bill enables up to 15 community-practice sites (not just hospitals or nursing homes) to participate in the program, selected based on applications demonstrating readiness, which may allow innovative, local healthcare partnerships and extend services beyond traditional hospital settings.
Maintains oversight and patient choice. The legislation preserves important safeguards: participation is voluntary for all parties, the primary provider’s judgment prevails in disagreements, and patients must give written consent—ensuring patient autonomy and clinical oversight are not compromised as the program grows.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Let Nurse Practitioners Manage Meds
Plain English, a few words. Used as the page title.
Sponsors
History
- Referred to higher education
- Referred to higher education
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Let Nurse Practitioners Manage Meds
In Assembly Committee · Higher Education · Sponsor Rebecca Seawright
Full text
4 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
4689
2021-2022 Regular Sessions
IN SENATE
February 8, 2021
Introduced by Sen. RIVERA -- read twice and ordered printed, and when printed to be committed to the Committee on Higher Education
AN ACT to amend the education law, in relation to including nurse practitioners as a provider of services for purposes of collaborative drug therapy management; and to amend chapter 21 of the laws of 2011 amending the education law relating to authorizing pharmacists to perform collaborative drug therapy management with physicians in certain settings, in relation to making the authorization for pharmacists to perform collaborative drug therapy management permanent
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Section 6801-a of the education law, as amended by chapter 238 of the laws of 2015, is amended to read as follows:
§ 6801-a. Collaborative drug therapy management [demonstration program]. 1. As used in this section, the following terms shall have the following meanings:
a. "Board" shall mean the state board of pharmacy as established by section sixty-eight hundred four of this article.
b. "Clinical services" shall mean the collection and interpretation of patient data for the purpose of initiating, modifying and monitoring drug therapy with associated accountability and responsibility for outcomes in a direct patient care setting.
c. "Collaborative drug therapy management" shall mean the performance of clinical services by a pharmacist relating to the review, evaluation and management of drug therapy to a patient, who is being treated by a physician or nurse practitioner for a specific disease or associated disease states, in accordance with a written agreement or protocol with a voluntarily participating physician or nurse practitioner and in accordance with the policies, procedures, and protocols of the facility. Such agreement or protocol as entered into by the physician or nurse practitioner and a pharmacist, may include, and shall be limited to:
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD05638-01-1
S. 4689 2
(i) adjusting or managing a drug regimen of a patient, pursuant to a patient specific order or protocol made by the patient's physician or nurse practitioner, which may include adjusting drug strength, frequency of administration or route of administration. Adjusting the drug regimen shall not include substituting or selecting a different drug which differs from that initially prescribed by the patient's physician or nurse practitioner unless such substitution is expressly authorized in the written order or protocol. The pharmacist shall be required to immediately document in the patient record changes made to the patient's drug therapy and shall use any reasonable means or method established by the facility to notify the patient's other treating physicians or nurse practitioners with whom he or she does not have a written agreement or protocol regarding such changes. The patient's physician or nurse practitioner may prohibit, by written instruction, any adjustment or change in the patient's drug regimen by the pharmacist;
(ii) evaluating and, only if specifically authorized by the protocol and only to the extent necessary to discharge the responsibilities set forth in this section, ordering disease state laboratory tests related to the drug therapy management for the specific disease or disease state specified within the written agreement or protocol; and
(iii) only if specifically authorized by the written agreement or protocol and only to the extent necessary to discharge the responsibilities set forth in this section, ordering or performing routine patient monitoring functions as may be necessary in the drug therapy management, including the collecting and reviewing of patient histories, and ordering or checking patient vital signs, including pulse, temperature, blood pressure and respiration.
d. "Facility" shall mean: (i) a [teaching hospital or general] hospital, [including any diagnostic center, treatment center, or hospitalbased outpatient department] as defined in subdivision one of section twenty-eight hundred one of the public health law; or (ii) a nursing home with an on-site pharmacy staffed by a licensed pharmacist; provided, however, for the purposes of this section the term "facility" shall not include dental clinics, dental dispensaries, residential health care facilities and rehabilitation centers.
[For the purposes of this section, a "teaching hospital" shall mean a hospital licensed pursuant to article twenty-eight of the public health law that is eligible to receive direct or indirect graduate medical education payments pursuant to article twenty-eight of the public health law.] In addition, a facility may also include up to fifteen communitypractice sites, selected by the department in consultation with the department of health, where pharmacists and physicians or nurse practitioners may propose to enter into collaborative arrangements, pursuant to the provisions of this section. Such sites shall be selected based upon a review of applications submitted to the department by such pharmacists and physicians or nurse practitioners, which demonstrate that the applicants can satisfy the requirements of this section.
e. "Physician" or "nurse practitioner" shall mean the physician or nurse practitioner selected by or assigned to a patient, who has primary responsibility for the treatment and care of the patient for the disease and associated disease states that are the subject of the collaborative drug therapy management.
f. "Written agreement or protocol" shall mean a written document, pursuant to and consistent with any applicable state or federal requirements, that addresses a specific disease or associated disease states and that describes the nature and scope of collaborative drug therapy
S. 4689 3
management to be undertaken by the pharmacists, in collaboration with the participating physician or nurse practitioner in accordance with the provisions of this section.
2. a. A pharmacist who meets the experience requirements of paragraph b of this subdivision and who is either employed by or otherwise affiliated with a facility or is participating with a community-practice site selected pursuant to paragraph d of subdivision one of this section shall be permitted to enter into a written agreement or protocol with a physician or nurse practitioner authorizing collaborative drug therapy management, subject to the limitations set forth in this section, within the scope of such employment [or], affiliation or participation.
b. A participating pharmacist must:
(i)(A) have been awarded either a master of science in clinical pharmacy or a doctor of pharmacy degree;
(B) maintain a current unrestricted license; and
(C) have a minimum of two years experience, of which at least one year of such experience shall include clinical experience in a health facility, which involves consultation with physicians or nurse practitioners with respect to drug therapy and may include a residency at a facility involving such consultation; or
(ii)(A) have been awarded a bachelor of science in pharmacy;
(B) maintain a current unrestricted license; and
(C) within the last seven years, have a minimum of three years experience, of which at least one year of such experience shall include clinical experience in a health facility, which involves consultation with physicians or nurse practitioners with respect to drug therapy and may include a residency at a facility involving such consultation; and
(iii) meet any additional education, experience, or other requirements set forth by the department in consultation with the board.
c. Notwithstanding any provision of law, nothing in this section shall prohibit a licensed pharmacist from engaging in clinical services associated with collaborative drug therapy management, in order to gain experience necessary to qualify under clause (C) of subparagraph (i) or (ii) of paragraph b of this subdivision, provided that such practice is under the supervision of a pharmacist that currently meets the referenced requirement, and that such practice is authorized under the written agreement or protocol with the physician or nurse practitioner.
d. Notwithstanding any provision of this section, nothing herein shall authorize the pharmacist to diagnose disease. In the event that a treating physician or nurse practitioner may disagree with the exercise of professional judgment by a pharmacist, the judgment of the treating physician or nurse practitioner shall prevail.
3. The physician or nurse practitioner who is a party to a written agreement or protocol authorizing collaborative drug therapy management shall be employed by or otherwise affiliated with the same facility with which the pharmacist is also employed or affiliated.
4. The existence of a written agreement or protocol on collaborative drug therapy management and the patient's right to choose to not participate in collaborative drug therapy management shall be disclosed to any patient who is eligible to receive collaborative drug therapy management. Collaborative drug therapy management shall not be utilized unless the patient or the patient's authorized representative consents, in writing, to such management. If the patient or the patient's authorized representative consents, it shall be noted on the patient's medical record. If the patient or the patient's authorized representative who consented to collaborative drug therapy management chooses to no longer
S. 4689 4
participate in such management, at any time, it shall be noted on the patient's medical record. In addition, the existence of the written agreement or protocol and the patient's consent to such management shall be disclosed to the patient's primary physician or nurse practitioner and any other treating physician or nurse practitioner or healthcare provider.
5. Participation in a written agreement or protocol authorizing collaborative drug therapy management shall be voluntary, and no patient, physician or nurse practitioner, pharmacist, or facility shall be required to participate.
6. Nothing in this section shall be deemed to limit the scope of practice of pharmacy nor be deemed to limit the authority of pharmacists and physicians or nurse practitioners to engage in medication management prior to the effective date of this section and to the extent authorized by law.
§ 2. Section 5 of chapter 21 of the laws of 2011 amending the education law relating to authorizing pharmacists to perform collaborative drug therapy management with physicians in certain settings, as amended by section 20 of part BB of chapter 56 of the laws of 2020, is amended to read as follows:
§ 5. This act shall take effect on the one hundred twentieth day after it shall have become a law[, provided, however, that the provisions of sections two, three, and four of this act shall expire and be deemed repealed July 1, 2022]; provided, however, that the amendments to subdivision 1 of section 6801 of the education law made by section one of this act shall be subject to the expiration and reversion of such subdivision pursuant to section 8 of chapter 563 of the laws of 2008, when upon such date the provisions of section one-a of this act shall take effect; provided, further, that effective immediately, the addition, amendment and/or repeal of any rule or regulation necessary for the implementation of this act on its effective date are authorized and directed to be made and completed on or before such effective date.
§ 3. This act shall take effect on the one hundred twentieth day after it shall have become a law. Effective immediately, the addition, amendment and/or repeal of any rule or regulation necessary for the implementation of this act on its effective date are authorized to be made and completed on or before such effective date.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the education law, in relation to including nurse prac- titioners as a provider of services for purposes of collaborative drug therapy management; and to amend chapter 21 of the laws of 2011 amending the education law relating to authorizing pharmacists to perform colla- borative drug therapy management with physicians in certain settings, in relation to making the authorization for pharmacists to perform collabo- rative drug therapy management permanent
Purpose or general idea of bill
To extend and expand provisions enacted in 2011 that permit pharmacists to collaborate with physicians in the provision of collaborative drug therapy.
Summary of provisions
The bill would extend and make permanent the Collaborative Drug Therapy Demonstration Project and expand the scope of the authorization for collaborative drug therapy management (CDTM) as follows: Section one of the bill would amend section 6801-a of the Education Law as follows: *Deletes reference to a "demonstration program" in the title of the section;*Adds nurse practitioners (NPs) to the legislation to allow NPs to enter into collaborative agreements with pharmacists by which drug therapies would be reviewed, evaluated and managed;*Authorizes CDTM to occur in all hospitals and other Article 28 facilities, such as nursing homes and clinics; and *Permits the State Education Department in consultation with the Department of Health, to include up to fifteen community practice sites as authorized locations for the provision of CDTM.
Read the full memo (885 words)
Section two of the bill would repeal the expiration date of the prior statute and make the provisions permanent.
Difference between original and amended version (if applicable)
Section 6801-a established the CDTM Demonstration Program and authorized physicians and pharmacists in teaching hospitals (including clinics associated with them) to engage in collaborative drug therapy manage- ment. The existing law authorizes pharmacists and physicians, pursuant to protocols entered into between them, to adjust and manage a drug regimen of a patient, including adjusting drug strength, frequency of administration and route of administration. If authorized by the proto- col, the substitution of a different drug may also be permitted. In addition, requirements relating to follow up with the patient's treating physicians, the qualifications of the pharmacists and various other requirements and limitations exist in the current law.
Justification
Legislation was enacted in 2011 to establish the Collaborative Drug Therapy Management Demonstration Program, by which pharmacists, working in collaborative agreements with physicians, could adjust, manage, eval- uate and implement drug therapies for patients in certain settings. The current law only applies to teaching hospitals and their affiliated outpatient and freestanding clinics. A report on the results of the current statute will be issued in late 2013 or early 2014 but all preliminary reports have indicated that the legislation has been successfully implemented by eligible facilities and the collaboration between pharmacists and physicians has been very much in the interest of promoting the best interests of their patients. This bill would extend the current program to all Article 28 licensed health care facilities (hospitals, clinics and residential health care facilities) as well as permit the practice on a more limited basis in certain community based settings. The bill would also permit nurse practitioners to engage in the collaborative agreements with pharmacists.Adverse drug reactions or adverse drug events (ADRs or ADEs) are reported to be among the leading causes of death in the United States, behind only heart disease, cancer and stroke. The most updated $ information on ADRs suggests that these earlier estimates may actually under- state the problem. A recent comprehensive study of medication errors, estimated that as many as 2.7 million medication errors occur each year in hospitals in the United States, adversely affecting 130,000 patients. Studies have shown that at least 28% of these errors were preventable. Nearly half of the errors made were the result of errors in the prescribing process. These errors are not only potentially dangerous to patients, they are extremely cost- ly to the health care system, resulting in additional and unnecessary expenditures of as much as $177 billion per year. Of this amount, seven- ty percent was attributed to unnecessary hospital admissions or prolonged hospital stays due to medication errors.Virtually every other state permits CDTM, most of which authorize the practice in many more settings than permitted under the current New York State law and the results have been uniformly positive: CDTM along with pharmacist provided drug information services, adverse drug reaction monitoring, drug protocol management and medial rounds participation by pharmacists have all shown to make a statistically significant contribution to the reduction of medication errors. The expansion of the statute to addi- tional settings and the authorizing of Nurse Practitioners as collab- orating practitioners is warranted not only by the success of the New York State initiative, but based on the records of other states.
Prior legislative history
2021-2022: New Bill / A1036
2019-2020: A3048 Seawright
2017-2018: S4296 Lavalle /A10196
2015-2016: S280 Lavalle
Fiscal implications for state and local governments
None.
Effective date
This act shall take effect on the one hundred twentieth day after it shall have become a law; provided that, effective immediately, the addi- tion, amendment and/or repeal of any rule or regulation necessary for the implementation of this act on its effective date are authorized and directed to be made and completed on or before such effective date.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.